Revenio Group (REG1V.HE) Stock Analysis & AI Equity Report
Revenio Group (REG1V.HE) overview
Revenio Group (REG1V.HE) stock analysis and AI equity research. For the latest completed financial year, 2024, Revenio Group reported revenue of EUR 104m and operating profit of EUR 25.1m; the year-end share price was 26.58 EUR and market capitalisation was EUR 707m. Revenio Group is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Revenio Group's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-23. Data will be refreshed during report generation.
About Revenio Group
Revenio Group is a global provider of eye care diagnostic and vision care technology. It sells tonometers, retinal imaging devices, perimeters, OCT and refraction systems, plus clinical software under the iCare and Visionix brands. The company serves optometry, optical retail and ophthalmology, and in 2026 expanded through the acquisition of Visionix.
Generate the Revenio Group report
Revenio Group is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Revenio Group and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.